BioCentury | Mar 9, 2018
Clinical News

Vanda's Hetlioz meets in Phase III for jet lag disorder

...Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Hetlioz tasimelteon (VEC-162) Business: Neurology Molecular target: Melatonin MT1 receptor...
...and visual analog scale (VAS) Status: Phase III data Milestone: NA Chris Lieu Hetlioz tasimelteon VEC-162 Bristol-Myers Squibb Co. Vanda Pharmaceuticals Inc. Melatonin MT1 receptor Melatonin...
BioCentury | Feb 16, 2018
Clinical News

Neurim's PedPRM meets in Phase III for insomnia in children with autism

...of melatonin. Neurim Pharmaceuticals Ltd., Tel Aviv, Israel Product: PedPRM melatonin Business: Neurology Molecular target: Melatonin MT1 receptor...
...life (QOL) and satisfaction of child’s sleep Status: Phase III data Milestone: NA Claire Quang Neurim Pharmaceuticals Ltd. Melatonin MT1 receptor Melatonin...
BioCentury | Oct 10, 2016
Clinical News

Piromelatine: Phase II started

...Pharmaceuticals Ltd. , Tel Aviv, Israel Product: Piromelatine ( Neu-P11 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
BioCentury | Feb 25, 2013
Clinical News

Piromelatine: Phase II data

...Pharmaceuticals Ltd. , Tel Aviv, Israel Product: Piromelatine ( Neu-P11 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
BioCentury | Feb 4, 2013
Clinical News

Tasimelteon: Development discontinued

...Squibb Co. (NYSE:BMY), New York, N.Y. Product: Tasimelteon ( VEC-162 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
BioCentury | Jan 28, 2013
Clinical News

Tasimelteon: Additional Phase III data

...Squibb Co. (NYSE:BMY), New York, N.Y. Product: Tasimelteon ( VEC-162 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
BioCentury | Dec 24, 2012
Clinical News

Tasimelteon: Phase III data

...Squibb Co. (NYSE:BMY), New York, N.Y. Product: Tasimelteon ( VEC-162 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
BioCentury | Jan 30, 2012
Clinical News

Tasimelteon: Preliminary Phase III data

...Squibb Co. (NYSE:BMY), New York, N.Y. Product: Tasimelteon ( VEC-162 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
BioCentury | Nov 14, 2011
Clinical News

Tasimelteon: Phase IIb/III started

...Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Rockville, Md. Product: Tasimelteon ( VEC-162 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
BioCentury | Nov 7, 2011
Clinical News

Valdoxan agomelatine: Development discontinued

...Basel, Switzerland Product: Valdoxan agomelatine ( Thymanax )) ( AGO178 ) Business: Neurology Molecular target: Melatonin MT1 receptor...
Items per page:
1 - 10 of 36